Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
I'm LongbridgeAI, I can summarize articles.Celldex Therapeutics has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints. Although the drug successfully depleted mast cells, it did not relieve chronic itch symptoms compared to placebo. Consequently, Celldex shares dropped 6.06% in premarket trading.
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules.
The discontinuation comes after the study failed to achieve its primary and key secondary objectives.
Suboptimal Clinical Outcomes
The 24-week, double-blind, placebo-controlled study enrolled 140 participants with moderate to severe symptoms who lacked adequate responses to topical medications.
The trial’s primary goal was to observe a four-point or greater improvement on the worst itch numeric rating scale at the 12-week mark.
The percentage of patients reaching this milestone showed no meaningful differentiation from the placebo group.
Read Also: Cyclospora Cases Rise to 4,173 as Recalled Lettuce Outbreak Spreads Across 41 States, Even as Robert F. Kennedy Jr. Says Situation 'Under Control'
Secondary targets, including the investigator global assessment for skin lesions, were equally unsuccessful. Furthermore, extending the active treatment and evaluation period to 24 weeks yielded no additional clinical improvements.
Biological Impact And Safety Profile
Barzolvolimab is a novel humanized monoclonal antibody designed to target and deplete mast cells.
The treatment successfully triggered a rapid, profound, and sustained reduction in circulating tryptase, clearly confirming systemic mast cell depletion.
However, this biological response did not translate into symptom relief, leading researchers to conclude that mast cells may not be the central pathogenic driver of prurigo nodularis.
Despite the lack of clinical efficacy, the drug remained extremely well-tolerated.
The administered regimen, featuring an initial 450mg loading dose followed by ongoing 150mg or 300mg doses every four weeks, maintained a favorable safety profile consistent with previous clinical observations.
Following the main phase, patients were monitored for an additional 16 weeks, though the primary investigation is now halted.
In August 2025, Celldex stopped developing barzolvolimab in eosinophilic esophagitis (EoE) as the drug did not improve EoE symptoms or endoscopic assessment of disease activity compared to placebo.
CLDX Price Action: Celldex Therapeutics shares were down 6.06% at $33.50 during premarket trading on Wednesday, according to Benzinga Pro data.
Read Also: Private Equity Strikes Again: A Roll-Up Strategy For America's Bowling Alleys Faces Gut Check
Photo by Pavel Kapysh via Shutterstock